Immunohistochemical and mutational status of telomerase reverse transcriptase in conjunctival squamous cell carcinoma.
Conjunctival
TERT
UV signature mutations
immunohistochemistry
ocular surface squamous cell carcinoma
Journal
Indian journal of ophthalmology
ISSN: 1998-3689
Titre abrégé: Indian J Ophthalmol
Pays: India
ID NLM: 0405376
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
entrez:
28
2
2022
pubmed:
1
3
2022
medline:
22
3
2022
Statut:
ppublish
Résumé
Mutations in human telomerase reverse transcriptase (TERT) are associated with increased telomerase activity in cutaneous melanomas. Conjunctival squamous cell carcinoma, also referred to as ocular surface squamous cell carcinoma, is cancer on the surface of the eye. Recent studies have identified UV signat`ure mutations in TERT promoters in ocular melanoma and ocular surface squamous neoplasia. However, its immunohistochemical status has not been reported in ocular surface squamous cell carcinoma. This study aimed to explore the immunohistochemical and mutational status of TERT in ocular surface SCC. The immunohistochemical expression of TERT and mutational status of TERT promoter was evaluated in 19 ocular surface squamous cell carcinoma cases. Conjunctival melanoma tissue was used as a positive control. The cytoplasmic overexpression of TERT was detected in 11/19 (57%), and TERT promoter mutations were identified in 6/19 (31%) of ocular surface squamous cell carcinoma. Out of these, 66% had a C228T mutation, and 33% had a C250T mutation. The TERT expression was found to be associated with a high (≥T3) AJCC category (P = 0.023), and TERT immunoexpression was significantly correlated with reduced disease-free survival (P = 0.024, log-rank analysis) in ocular surface squamous cell carcinoma patients. The present study demonstrates that TERT promoter mutations with UV signatures are frequent in ocular surface squamous cell carcinoma. The increased expression of TERT could be of biological significance in aggressive ocular surface squamous cell carcinoma.
Identifiants
pubmed: 35225554
pii: IndianJOphthalmol_2022_70_3_971_338164
doi: 10.4103/ijo.IJO_1342_21
pmc: PMC9114615
doi:
Substances chimiques
TERT protein, human
EC 2.7.7.49
Telomerase
EC 2.7.7.49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
971-975Déclaration de conflit d'intérêts
None
Références
Mod Pathol. 2014 Apr;27(4):516-23
pubmed: 24030752
Lancet. 1996 May 25;347(9013):1450-1
pubmed: 8676629
Science. 2013 Feb 22;339(6122):959-61
pubmed: 23348503
Science. 1994 Dec 23;266(5193):2011-5
pubmed: 7605428
Nucleic Acids Res. 2007;35(4):1245-56
pubmed: 17267411
Community Eye Health. 2016;29(95):52-53
pubmed: 28289320
Nat Commun. 2014 Feb 26;5:3401
pubmed: 24569790
Cell. 1993 Sep 24;74(6):957-67
pubmed: 8402885
Br J Ophthalmol. 2016 Feb;100(2):274-7
pubmed: 26472403
Toxicol Appl Pharmacol. 2007 Nov 1;224(3):241-8
pubmed: 17270229
J Biomed Sci. 2018 Mar 12;25(1):22
pubmed: 29526163
Int Ophthalmol Clin. 2010 Summer;50(3):35-46
pubmed: 20611016
Pigment Cell Melanoma Res. 2016 May;29(3):391-3
pubmed: 26928778
Oncotarget. 2016 Oct 25;7(43):69173-69187
pubmed: 27732951
Trends Genet. 2014 Oct;30(10):430-8
pubmed: 25172021
Int J Cancer. 1997 Oct 21;74(5):535-9
pubmed: 9355977
Invest Ophthalmol Vis Sci. 2015 Sep;56(10):5854-61
pubmed: 26348634
Endocr Pathol. 2018 Dec;29(4):380-383
pubmed: 30306386
J Clin Invest. 2019 Jan 2;129(1):223-229
pubmed: 30358567
PLoS One. 2013 Nov 18;8(11):e80354
pubmed: 24260374
Mol Cell Biol. 2000 May;20(10):3705-14
pubmed: 10779360
Science. 2015 Feb 27;347(6225):1006-10
pubmed: 25722414
Oncogene. 2020 Sep;39(36):5811-5824
pubmed: 32733068
Medicine (Baltimore). 2018 Aug;97(35):e11794
pubmed: 30170373
Br J Cancer. 2018 Jan;118(1):98-105
pubmed: 29123258
Br J Ophthalmol. 2004 Apr;88(4):595-6
pubmed: 15031196
Oncotarget. 2015 Apr 30;6(12):10617-33
pubmed: 25797251